Holen Sie sich die Stockscreener-App
0.1716
4.73%
-0.0081
Schlusskurs vom Vortag:
$0.1797
Offen:
$0.1675
24-Stunden-Volumen:
39.53M
Relative Volume:
3.37
Marktkapitalisierung:
$3.44M
Einnahmen:
$19.57M
Nettoeinkommen (Verlust:
$-25.12M
KGV:
-0.0742
EPS:
-2.3114
Netto-Cashflow:
$-19.71M
1W Leistung:
-0.87%
1M Leistung:
-47.16%
6M Leistung:
-87.13%
1J Leistung:
-95.57%
1-Tages-Spanne:
$0.1657
$0.1812
1-Wochen-Bereich:
$0.164
$0.1928
52-Wochen-Spanne:
$0.1575
$3.9789
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.1712 | 3.62M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
106.02 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.81 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
273.46 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.59 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.44 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
Vivos to Issue 11.4M Shares to Settle $2.86M in Debt - Minichart
Vivos exchanges $2.9m debt for common stock with Streeterville By Investing.com - Investing.com Canada
Vivos exchanges $2.9m debt for common stock with Streeterville - Investing.com
Vivos Therapeutics Announces Material Debt Reduction - Yahoo Finance
Vivos Therapeutics Swaps $2.86M of Streeterville Debt for Up to 11.45M Shares - TradingView
Vivos Therapeutics Inc (NASDAQ: VVOS) Share Price, VVOS Stock News, VVOS Share Price & Updates - Kalkine
Vivos Therapeutics (VVOS) investor lists 122,963 shares, under 5% - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference - marketscreener.com
Vivos Therapeutics Surges as Investors Weigh Nevada Growth Updates and Florida Expansion Plan - Moomoo
Vivos Therapeutics partners with Florida cardiology group for sleep center - Investing.com
Vivos Therapeutics partners with Florida cardiology group for sleep center By Investing.com - Investing.com UK
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center - marketscreener.com
Vivos Therapeutics Inc. (VVOS) Peer Comparison – Compare with Others - Value Research
Vivos Therapeutics (VVOS) grants 250K shares, 150K options - Stock Titan
Vivos Therapeutics reports 212% rise in Nevada patient referrals By Investing.com - Investing.com Canada
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers - Barchart.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Vivos Therapeutics Inc (VVOS) Stock News Today - TradingKey
Vivos Therapeutics opens Henderson facility with $10M capacity - Investing.com
Vivos Therapeutics Opens Nevada Sleep Treatment Center - marketscreener.com
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment - The Manila Times
Vivos Therapeutics opens Henderson facility with $10M capacity By Investing.com - Investing.com Canada
Vivos Therapeutics Opens New Henderson Sleep Center, Expects Capacity to More Than Double to Over $10 Million Annually - Moomoo
Vivos expects its Nevada sleep center to more than double annual capacity to $10M+ - Stock Titan
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... By GuruFocus - Investing.com Canada
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
Vivos Therapeutics stock falls 6% on second quarter revenue miss By Investing.com - Investing.com Canada
Vivos Therapeutics stock falls 6% on second quarter revenue miss - Investing.com
Conferencia de resultados del 2T de 2026 de Vivos Therapeutics (VVOS): los ingresos suben un 35%, persisten los riesgos de liquidez - TradingKey
Vivos Therapeutics (VVOS) Q2 2026 Earnings Call: Umsatz steigt um 35 %, Liquiditätsrisiken bestehen weiterhin - TradingKey
Vivos Therapeutics partners with SPCVA to form AIM Florida - scanx.trade
Vivos Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Vivos Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Vivos gets Washington license to manufacture IsoPet - scanx.trade
Vivos Therapeutics reports 35% revenue increase in Q2 2026 - Investing.com India
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Vivos Therapeutics posts strong Q2 2026 revenue growth - Investing.com Canada
Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com - Investing.com Canada
Vivos Therapeutics Q2 revenue up 35%; targets positive cash flow by late 2026 - scanx.trade
Vivos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivos Therapeutics Q2 revenue rises 35% on service growth - TradingView
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results - Quiver Quantitative
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update - Yahoo Finance
Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics schedules Q2 2026 results, conference call - scanx.trade
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn - Stock Titan
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):